Intech Investment Management LLC increased its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 55.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 160,801 shares of the medical technology company’s stock after purchasing an additional 57,229 shares during the quarter. Intech Investment Management LLC’s holdings in Medtronic were worth $13,876,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Activest Wealth Management increased its stake in Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 259 shares during the last quarter. IAG Wealth Partners LLC acquired a new stake in Medtronic during the second quarter worth approximately $30,000. Team Financial Group LLC purchased a new stake in shares of Medtronic during the 3rd quarter worth approximately $31,000. Avion Wealth lifted its position in shares of Medtronic by 97.8% during the 3rd quarter. Avion Wealth now owns 362 shares of the medical technology company’s stock worth $31,000 after buying an additional 179 shares during the last quarter. Finally, Pin Oak Investment Advisors Inc. purchased a new stake in shares of Medtronic during the 2nd quarter worth approximately $32,000. 82.06% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Medtronic
In other news, EVP Michael Marinaro sold 10,420 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. The trade was a 8.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the transaction, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 61,903 shares of company stock worth $5,889,203. Company insiders own 0.27% of the company’s stock.
Medtronic News Roundup
Investors following MDT have been watching these news items:
- Positive Sentiment: Medtronic plans to acquire privately held Contego Medical for $380 million. Contego develops treatments for carotid artery disease and peripheral thrombectomy; the deal would expand Medtronic’s vascular portfolio and build on an existing U.S. distribution partnership. Medtronic to buy Contego Medical for $380M
- Negative Sentiment: Wall Street Zen lowered its rating on Medtronic shares, a potentially negative sentiment signal. The article listing does not specify the revised rating or rationale. Medtronic Stock Rating Lowered by Wall Street Zen
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Barclays upgraded shares of Medtronic to a “hold” rating in a research note on Wednesday, October 7th. TD Cowen reissued a “buy” rating and issued a $110.00 price target on shares of Medtronic in a research report on Wednesday, September 30th. Bank of America upped their price objective on shares of Medtronic from $95.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Finally, Wells Fargo & Company upped their price objective on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research note on Wednesday, September 2nd. Nineteen equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.88.
View Our Latest Analysis on MDT
Medtronic Price Performance
Medtronic stock opened at $102.92 on Tuesday. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. The business has a 50 day simple moving average of $93.89 and a 200-day simple moving average of $88.49. The stock has a market capitalization of $131.65 billion, a PE ratio of 25.35, a price-to-earnings-growth ratio of 2.36 and a beta of 0.56.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The firm had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same period last year, the company earned $1.26 earnings per share. The company’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts predict that Medtronic PLC will post 5.98 earnings per share for the current year.
Medtronic Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio (DPR) is 70.94%.
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
Recommended Stories
- Five stocks we like better than Medtronic
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
